




# SOLIQUA<sup>®</sup>

insulin glargine & lixisenatide injection



- **2 ACTIVE INGREDIENTS:**  
insulin glargine  
and lixisenatide<sup>1</sup>
- **1 FIXED RATIO  
COMBINATION** therapy<sup>1</sup>
- **ONCE DAILY** injection<sup>1\*</sup>

**NOW INCLUDED AS AN  
OPEN BENEFIT ON THE  
NIHB DRUG BENEFIT LIST**

See reverse for details.

SOLIQUA<sup>®</sup>, a fixed ratio combination of insulin glargine and lixisenatide, once-daily injection, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus inadequately controlled on basal insulin (<60 units daily) alone or in combination with metformin.<sup>1</sup>

NIHB=Non-Insured Health Benefit.

\* Refer to the Product Monograph for complete dosing and administration information.

# NIHB REIMBURSEMENT

Open label benefits are those drugs listed in the NIHB Drug Benefit List (DBL) which do not have established criteria or prior approval requirements.<sup>2</sup>

Consult the Product Monograph at <http://products.sanofi.ca/en/soliqua.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1.888.852.6887.

**References:** 1. SOLIQUA<sup>®</sup> Product Monograph, sanofi-aventis Canada Inc., July 6, 2018. 2. Non-Insured Health Benefit List, January 9, 2020.

Copyright © 2020 sanofi-aventis Canada Inc.  
All rights reserved.

SACA.LALI.20.01.0036

MEMBER OF  
INNOVATIVE MEDICINES CANADA

SANOFI 

 **SOLIQUA<sup>®</sup>**  
insulin glargine & lixisenatide injection